Transforming mental health
Our lead drug candidate is a fixed-dose combination of an SSRI and a micro-dose of ibogaine – a central nervous system stimulant.
Next Generation Therapeutics
for Mental Health Disorders
Activating Brain Plasticity Through Novel Molecules
to Overcome the Limitations of Existing Therapies
to Overcome the Limitations of Existing Therapies
Our goal is to lead the development of combination therapies that enhance neuroplasticity and improve psychiatric outcomes.
Once daily oral dosage form
No supervision
Designed for efficacy with minimal side effects
No interruption to daily lifestyle
Unleashing the therapeutic
potential of Ibogaine
IBOGAINE
Ibogaine is a powerful compound derived from the root bark of the iboga tree (Tabernanthe iboga), native to Central and West Africa.
Historically, it was marketed in France until the 1970s under the name Lambarène as a stimulant.
Today, ibogaine is at the forefront of cutting-edge research in the United States, being developed not only as a promising treatment for addiction but also for its potential to revolutionize depression therapy by enhancing neuroplasticity and addressing treatment-resistant cases.
Management
Itay is an entrepreneur with vast experience in the private and public sectors. He oversaw the first IPO of medical Cannabis company in the Tel Aviv Stock Exchange. Prior to PsyRx Itay served as the CEO of Hi-Pharma Ltd, a medical cannabis company for 2 years and 7 years as COO of Palgi Sharon - Israeli Municipal Water Corporation.
